Antibacterial Efficacy of Phages against Pseudomonas aeruginosa Infections in Mice and Drosophila melanogaster (cid:1)
暂无分享,去创建一个
[1] Shin-Young Park,et al. Drosophila melanogaster-Based Screening for Multihost Virulence Factors of Pseudomonas aeruginosa PA14 and Identification of a Virulence-Attenuating Factor, HudA , 2008, Infection and Immunity.
[2] D. Scholl,et al. Antibacterial Efficacy of R-Type Pyocins towards Pseudomonas aeruginosa in a Murine Peritonitis Model , 2008, Antimicrobial Agents and Chemotherapy.
[3] G. Lau,et al. Genome sequence comparison and superinfection between two related Pseudomonas aeruginosa phages, D3112 and MP22. , 2007, Microbiology.
[4] J. Fralick,et al. Phage Therapy of Pseudomonas aeruginosa Infection in a Mouse Burn Wound Model , 2007, Antimicrobial Agents and Chemotherapy.
[5] F. Ausubel,et al. Antifungal Chemical Compounds Identified Using a C. elegans Pathogenicity Assay , 2007, PLoS pathogens.
[6] You-Hee Cho,et al. R-type pyocin is required for competitive growth advantage between Pseudomonas aeruginosa strains. , 2007, Journal of microbiology and biotechnology.
[7] Tetsuya Matsumoto,et al. Efficacy of Bacteriophage Therapy against Gut-Derived Sepsis Caused by Pseudomonas aeruginosa in Mice , 2006, Antimicrobial Agents and Chemotherapy.
[8] Frederick M Ausubel,et al. Identification of novel antimicrobials using a live-animal infection model , 2006, Proceedings of the National Academy of Sciences.
[9] You-Hee Cho,et al. KatA, the Major Catalase, Is Critical for Osmoprotection and Virulence in Pseudomonas aeruginosa PA14 , 2005, Infection and Immunity.
[10] Toshikazu Tani,et al. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases , 2005, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[11] L. Steinstraesser,et al. Host defense peptides in burns. , 2004, Burns : journal of the International Society for Burn Injuries.
[12] U. Bläsi,et al. Therapy of Experimental Pseudomonas Infections with a Nonreplicating Genetically Modified Phage , 2004, Antimicrobial Agents and Chemotherapy.
[13] E. Anggard,et al. Therapeutic use of bacteriophages. , 2004, The Lancet. Infectious diseases.
[14] R. Gibson,et al. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management , 2003, Current opinion in pulmonary medicine.
[15] E. Mahenthiralingam,et al. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada. , 2002, American journal of respiratory and critical care medicine.
[16] L. Wilkinson. Félix d'Herelle and the origins of molecular biology , 2001, Medical History.
[17] H. Ackermann. Frequency of morphological phage descriptions in the year 2000 , 2001, Archives of Virology.
[18] N. Barekzi,et al. Efficacy of Locally Delivered Polyclonal Immunoglobulin against Pseudomonas aeruginosa Peritonitis in a Murine Model , 1999, Antimicrobial Agents and Chemotherapy.
[19] H. Ackermann. Tailed Bacteriophages: The Order Caudovirales , 1998, Advances in Virus Research.
[20] C. Goodwin,et al. Burn Wound Infections: Current Status , 1998, World Journal of Surgery.
[21] K. Iczkowski,et al. Bacteriophages show promise as antimicrobial agents. , 1998, The Journal of infection.
[22] M. Levison,et al. Peritonitis: update on pathophysiology, clinical manifestations, and management. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] Robert L. Erwin. Host-defense peptides , 1996, Nature Biotechnology.
[24] T. Hayashi,et al. Identification of the lipopolysaccharide core region as the receptor site for a cytotoxin-converting phage, phi CTX, of Pseudomonas aeruginosa , 1994, Journal of bacteriology.
[25] S. Santacroce,et al. Pseudomonas peritonitis associated with continuous ambulatory peritoneal dialysis: a six-year study. , 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[26] M. Gauderer,et al. Pseudomonas aeruginosa as a primary pathogen in children with bacterial peritonitis. , 1987, Journal of pediatric surgery.
[27] M. Dabrowski,et al. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. , 1987, Archivum immunologiae et therapiae experimentalis.
[28] H. O. Senekjian,et al. Pseudomonas peritonitis and continuous ambulatory peritoneal dialysis. , 1982, Archives of internal medicine.
[29] K. Jarrell,et al. Pseudomonas aeruginosa bacteriophage phi PLS27-lipopolysaccharide interactions , 1981, Journal of virology.
[30] J. Bartlett,et al. Experimental Intra-Abdominal Abscesses in Rats: Development of an Experimental Model , 1974, Infection and immunity.
[31] D. E. Bradley. The length of the filamentous Pseudomonas aeruginosa bacteriophage Pf. , 1973, The Journal of general virology.
[32] D. E. Bradley. A pilus-dependent Pseudomonas aeruginosa bacteriophage with a long noncontractile tail. , 1973, Virology.
[33] D. E. Bradley,et al. Ultrastructure of bacteriophage and bacteriocins , 1967, Bacteriological reviews.